Ocular Graft-Versus-Host Disease
Understanding Ocular Graft-Versus-Host Disease
When you receive a bone marrow or stem cell transplant, the donor cells become part of your immune system. Sometimes these new cells recognize tissues in your body as foreign and begin to attack them. Your eyes can become a target because they contain specialized glands and cells that the donor immune system may see as different. The lacrimal glands that produce your tears and the meibomian glands in your eyelids are particularly vulnerable to this immune attack.
As the donor immune cells damage these glands, your tear production decreases and the quality of your tears changes. The surface of your eyes becomes inflamed and irritated. This process can also affect the conjunctiva, the thin membrane covering the white part of your eye and the inside of your eyelids.
Ocular GVHD disrupts your tear film in multiple ways at once. The inflammation damages the glands that produce the watery layer of your tears, reducing the overall volume of tears on your eye surface. At the same time, the meibomian glands in your eyelids stop working properly, so they cannot produce the oily layer that prevents tears from evaporating too quickly.
- Decreased tear production from damaged lacrimal glands
- Poor oil layer function from inflamed meibomian glands
- Increased inflammation on the surface of your eyes
- Damage to the cells that maintain a smooth eye surface
- Rapid evaporation of the tears you do produce
Not everyone who develops GVHD in other parts of the body will develop eye symptoms. However, certain factors make ocular GVHD more likely. If you already have systemic GVHD affecting your skin, mouth, liver, or digestive system, your risk of developing eye involvement increases significantly.
Other risk factors include receiving donor cells from an unrelated person, having a female donor if you are male, older age at the time of transplant, and the type of conditioning treatment you received before your transplant. Chronic GVHD, which develops months or years after your transplant, more commonly affects the eyes than acute GVHD.
Most people with ocular GVHD notice eye symptoms as part of chronic GVHD rather than acute GVHD. Chronic GVHD usually begins at least three months after your transplant, though it can start much later. Eye symptoms may appear several months to years following your bone marrow or stem cell transplant.
In some cases, eye symptoms develop gradually and worsen over time. Other patients notice sudden onset of severe dry eye and discomfort. If you have already been diagnosed with GVHD in other organs, we recommend starting regular eye examinations even before symptoms begin, because early detection and treatment can help protect your eyes.
Recognizing Symptoms and Warning Signs
The first signs of ocular GVHD often feel similar to common dry eye, which can make them easy to dismiss at first. You might notice a gritty or sandy sensation, as if something is stuck in your eyes. Many patients describe a burning or stinging feeling, especially in environments with dry air or wind.
- A scratchy or foreign body sensation in one or both eyes
- Burning, stinging, or irritation that comes and goes
- Increased sensitivity to light or bright environments
- Redness that does not go away with rest
- Eyes that feel tired or strained by mid-day
As ocular GVHD progresses without treatment, symptoms become more severe and more constant. You may develop blurred vision that clears briefly when you blink but returns quickly. Some patients notice stringy or thick mucus collecting in the corners of their eyes. Your eyes might water excessively, which seems contradictory but happens because your eyes try to compensate for poor tear quality.
Advanced cases can cause significant pain rather than just discomfort. Your eyelids may become inflamed and crusty, especially along the lash line. You might find it difficult to open your eyes in the morning because secretions seal your lids shut overnight.
Certain symptoms signal that your ocular GVHD needs urgent evaluation. Sudden vision loss or a rapid decrease in your vision requires same-day assessment. Severe eye pain, especially if accompanied by increased redness or discharge, should prompt immediate contact with our office or your nearest emergency eye care provider.
A new white or gray spot on the clear front part of your eye (cornea), significant light sensitivity that makes it hard to keep your eyes open, or the sensation that a curtain is falling over your vision all require urgent attention. The curtain symptom is not typical of ocular GVHD but is still an eye emergency. These symptoms might indicate complications beyond dry eye, such as infection or corneal damage, which need immediate treatment to prevent permanent vision loss.
- A nonhealing defect on the cornea or a new white spot on the cornea
- Marked light sensitivity, severe pain, or copious discharge
- Rapidly worsening redness or swelling of eyelids
- Sudden drop in vision, especially in contact lens wearers
- Any new severe symptoms while you are immunosuppressed
While ocular GVHD shares many symptoms with other forms of dry eye disease, it tends to be more severe and resistant to standard treatments. The inflammation is driven by your immune system attacking your own eye tissues, not just by aging or environmental factors. Over-the-counter products may provide partial relief, but most patients need prescription or advanced therapies.
Ocular GVHD also usually affects both eyes, though one eye may be worse than the other. The condition tends to progress more rapidly than dry eye from other causes. Additionally, if you have ocular GVHD, you typically also have signs of GVHD in other parts of your body, such as your mouth, skin, or liver, which helps distinguish it from other dry eye conditions.
Diagnosis and Testing
When you come in for evaluation of possible ocular GVHD, we start with a thorough discussion of your transplant history and current symptoms. We will ask about when you had your transplant, whether you have GVHD affecting other organs, what medications you are taking, and how your eye symptoms affect your daily activities. This background helps us understand your individual risk and tailor our examination.
We then carefully examine the outside of your eyes, checking your eyelids for inflammation, your blink pattern, and how your tears coat the eye surface. We look at the blood vessels on the whites of your eyes to assess inflammation. Every part of this examination gives us clues about the severity and type of eye surface damage you may have. We may also perform a dilated eye examination to check the back of the eye when indicated, especially if you are on systemic steroids or at risk for opportunistic infections.
The Schirmer test measures how much tear volume your eyes produce. We place a small strip of filter paper inside your lower eyelid and ask you to close your eyes gently for five minutes. The tears that your eyes make during this time travel along the paper strip. After five minutes, we measure how far the moisture traveled on the paper. Lower measurements indicate reduced tear production. The test can be performed with or without topical anesthesia, and results may vary between visits.
- Normal results show at least 10 to 15 millimeters of wetting
- Mild dry eye produces 5 to 10 millimeters of wetting
- Severe dry eye results in less than 5 millimeters
- The test may cause temporary irritation or tearing
- Tear breakup time under 10 seconds is abnormal
We use special dyes to highlight damage on the surface of your eyes. Fluorescein is an orange dye that glows green under blue light and shows areas where cells on your cornea are damaged or missing. Lissamine green is another dye that highlights unhealthy cells on your conjunctiva and cornea. These staining patterns help us determine the severity and location of surface damage.
Using a slit lamp microscope, we examine your eyes at high magnification. This lets us see fine details of your tear film, cornea, conjunctiva, and eyelids. We look for signs of inflammation, scarring, blood vessel growth, and other changes characteristic of ocular GVHD. The slit lamp examination also helps us rule out other conditions that might be causing or contributing to your symptoms.
To standardize care and monitor your progress, we use validated scoring systems and objective measurements. These tools help us decide when to escalate treatment and show whether your therapy is working over time.
- NIH eye score 0 to 3 for ocular GVHD severity based on symptoms and signs
- Symptom questionnaires such as OSDI or DEQ-5 at baseline and follow-up visits
- Oxford or NEI staining scales to quantify corneal and conjunctival staining
- Meibography to assess meibomian gland loss and structure
- Tear osmolarity and MMP-9 testing when available to measure inflammation
- Schirmer testing with and without topical anesthesia, noting variability and limited specificity in ocular GVHD
Managing ocular GVHD requires teamwork between our office and your transplant physician or oncologist. We communicate with your primary transplant team about your eye findings and how they relate to GVHD in other organs. Sometimes adjustments to your systemic immunosuppressive medications can help improve your eye symptoms as well as other GVHD manifestations.
We share our treatment plans with your transplant doctor to make sure all your therapies work together safely. Your transplant team provides us with important information about your overall health status, transplant timeline, and other medications you take. This collaboration ensures you receive comprehensive, coordinated care that addresses both your eye health and your overall recovery from transplant.
Treatment Options for Ocular GVHD
We typically begin treatment with preservative-free artificial tears used frequently throughout the day. Preservatives in regular eye drops can further damage your already inflamed eye surface, so preservative-free formulas are essential for frequent use. You may need to use these drops every hour or even more often initially to keep your eyes comfortable and protected.
At bedtime, we often recommend a preservative-free lubricating ointment because it stays on your eye surface longer while you sleep. Ointment can temporarily blur your vision, which is why we suggest using it only at night. Some patients also benefit from gel formulations during the day, which last longer than regular drops but do not blur vision as much as ointment.
For most patients with ocular GVHD, artificial tears alone are not enough to control the inflammation. We may recommend prescription anti-inflammatory eye drops that target the immune processes damaging your eye surface. Cyclosporine ophthalmic emulsion works by reducing inflammation and helping your tear-producing glands function better over time.
- Cyclosporine typically takes several weeks to months to show full benefit
- Lifitegrast works through a different anti-inflammatory pathway
- Both medications are typically used twice daily
- Some patients experience temporary stinging when starting these drops
- Consistent use is important for the best results
For moderate to severe inflammation or flares, we may use short courses of topical corticosteroids to provide rapid relief while slower steroid-sparing therapies take effect. Steroid drops reduce inflammation quickly but require careful monitoring to avoid serious side effects.
- Examples include loteprednol or fluorometholone for milder disease; prednisolone acetate or difluprednate for severe cases
- Taper based on response and minimize duration to reduce risks
- Risks include increased eye pressure, glaucoma, cataract, delayed healing, and infection reactivation
- We check intraocular pressure at baseline and every 2 to 4 weeks during initiation or dose increases
- Often combined with cyclosporine or lifitegrast to reduce long-term steroid exposure
Autologous serum tears are eye drops made from your own blood. We work with a specialized pharmacy or laboratory to create these drops from a sample of your blood. The serum contains growth factors, vitamins, and other natural substances that help heal your eye surface and reduce inflammation. These drops are particularly helpful for severe ocular GVHD that has not responded well to other treatments.
Typical concentrations range from 20 to 50 percent, used 4 to 8 times daily. Open vials are refrigerated and discarded per lab protocol, while unopened vials are kept frozen. Because autologous serum tears are made from your own blood, you thaw a small bottle at a time and keep it refrigerated for about a week. The preparation process and storage requirements make these drops more complex to use than commercial products, but many patients find them significantly more effective for severe dry eye from GVHD.
- Platelet-rich plasma tears if autologous serum is not available
- Allogeneic serum tears with infectious disease screening from qualified donors
- Umbilical cord serum tears as an alternative option
- We coordinate with your transplant team to ensure safety and assess whether you can donate blood
Scleral lenses are large-diameter specialty contact lenses that vault over your cornea and rest on the white part of your eye. They create a fluid reservoir over the cornea that protects the surface and improves comfort and vision in moderate to severe ocular GVHD.
- Consider when symptoms or surface disease persist despite maximal medical drops
- No overnight wear; lenses must be removed each evening
- Fill lenses with preservative-free sterile saline only before insertion
- Never use tap water on lenses or cases due to infection risk
- Strict hygiene and training are required, with close follow-up visits
- We reassess lens fit and corneal health regularly to ensure safety
Punctal plugs are tiny devices we insert into the drainage openings in the inner corners of your eyelids. By blocking these tear drains, we help the tears you do produce stay on your eye surface longer. Punctal plugs come in temporary and longer-lasting varieties. We often start with temporary plugs to make sure they help before considering more permanent options.
Moisture chamber glasses or goggles create a humid environment around your eyes, reducing tear evaporation. These specialized eyewear options have foam or silicone barriers that seal against your face. Some patients wear them at night, while others find them helpful when outdoors or in air-conditioned environments. We may also recommend using a humidifier at home and wearing wraparound sunglasses outside to minimize air flow across your eyes.
We avoid punctal occlusion when there is active infection, severe surface inflammation, or heavy mucus, since trapping inflammatory tears can worsen symptoms. We usually trial temporary plugs first and consider punctal cautery only if plugs repeatedly fall out and the surface is stable.
For severe cases or nonhealing defects, we may use procedures that promote healing and reduce scarring. These interventions are typically reserved for patients who do not respond adequately to medical therapy alone.
- Cryopreserved amniotic membrane devices or sutured grafts for epithelial defects and severe inflammation
- Bandage lenses only with caution due to infection risk in immunosuppressed patients
- Temporary tarsorrhaphy for exposure and persistent defects that do not heal
- Punctal cautery for long-term tear retention in carefully selected stable patients
Because ocular GVHD is one manifestation of your body's overall graft-versus-host reaction, treating the systemic disease often helps your eye symptoms. Your transplant doctor manages your immunosuppressive medications, which may include drugs like corticosteroids, tacrolimus, or other agents that calm your immune system. Modern systemic options such as ruxolitinib, belumosudil, ibrutinib, or extracorporeal photopheresis may help overall GVHD, although ocular disease often requires dedicated local therapy. When your systemic GVHD is better controlled, your eye inflammation often improves as well.
We work closely with your transplant team to monitor how changes in your systemic treatment affect your eyes. Sometimes your doctors may adjust your medications specifically to address worsening ocular symptoms. The goal is to find the right balance of immunosuppression that controls GVHD while minimizing side effects and maintaining your overall health.
Daily Management and Self-Care
Between visits to our office, there are many steps you can take at home to manage your symptoms. Clean your eyelids gently each day with warm water or a lid cleanser recommended by our eye doctor. This removes debris and helps your meibomian glands function better. Apply warm compresses to your closed eyelids for several minutes once or twice daily to help liquify oils in your eyelid glands.
- Take regular breaks from screens using the 20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds
- Remember to blink fully and frequently, especially during computer work or reading
- Stay well hydrated by drinking plenty of water throughout the day
- Avoid smoke, wind, and other eye irritants whenever possible
- Position fans and vents so they do not blow air directly toward your face
- Avoid over-the-counter redness reliever drops because they can worsen dryness and irritation
While no diet can cure ocular GVHD, certain nutrients may help support your overall eye health and tear function. Omega-3 fatty acids, found in fatty fish like salmon and sardines or in fish oil supplements, may help reduce inflammation and improve the oil layer of your tears. Evidence for omega-3 supplements in dry eye is mixed. If used, they should be approved by your transplant team due to potential bleeding risk and medication interactions.
Before starting any supplements, talk with both our office and your transplant doctor. Some supplements can interact with your immunosuppressive medications or affect your blood counts. Your transplant team needs to approve any new supplements you want to try. Foods rich in vitamins A, C, and E, as well as staying well hydrated, generally support healthy eyes without posing medication interaction risks.
The environment around you has a major impact on your eye comfort. Dry indoor air, especially during winter when heating systems run constantly, makes dry eye symptoms worse. Using a humidifier in rooms where you spend the most time can significantly improve your comfort. Aim for indoor humidity levels between 30 and 50 percent.
Reduce direct air flow across your eyes by repositioning your desk or bed away from vents and fans. When driving, angle air vents away from your face. Limit your time in environments that worsen symptoms, such as windy outdoor areas, smoky places, or overly air-conditioned spaces. When you must be in challenging environments, use moisture chamber glasses for protection.
- Use moisture chamber glasses during activities that aggravate symptoms, including indoor heating or air conditioning
- Wear wraparound sunglasses outdoors to reduce wind and glare
- Keep windows closed on dry or windy days
Managing ocular GVHD often requires using multiple types of eye drops on different schedules. This can feel overwhelming at first. We recommend creating a written schedule or setting phone alarms to help you remember each medication. Start your day with your morning drops, then keep a bottle of preservative-free tears with you at all times for frequent use.
If you use more than one prescription drop, separate them by at least 5 to 10 minutes to minimize washout. When you need to use two different drops close together, wait at least five minutes between them so the first drop is not washed out by the second. Apply ointment last, at bedtime, since it can interfere with how other drops absorb. Some patients find it helpful to connect their drop routine to daily habits like meals or brushing teeth. The most important thing is consistency, as skipped doses reduce the effectiveness of your treatment plan.
Follow-Up Care and Long-Term Outlook
When you are first diagnosed with ocular GVHD or starting new treatments, you may need to visit our office every few weeks. These frequent visits let us monitor how well your treatments are working and make adjustments quickly if needed. As your condition stabilizes, we typically extend the time between appointments to every few months.
Even when your symptoms are well controlled, you will likely need ongoing eye care for as long as you have GVHD. Some patients continue regular visits every three to six months indefinitely. Your specific follow-up schedule depends on the severity of your ocular GVHD, how stable your condition is, and whether you have other eye conditions that need monitoring.
At every follow-up appointment, we ask about your symptoms and any changes since your last visit. We repeat many of the same tests we performed at your initial evaluation, including checking your vision, examining your eye surface and tear film, and possibly repeating tear function tests. This allows us to track whether your condition is improving, staying stable, or worsening.
- Visual acuity to detect any changes in your eyesight
- Tear film quality and how well your tears coat your eyes
- Ocular surface staining to measure corneal and conjunctival damage
- Eyelid health and meibomian gland function
- Overall inflammation and any signs of complications
- Intraocular pressure, especially if you are using or have recently used steroid drops
- Lens clarity for steroid-associated cataract development
Your treatment plan is not set in stone. We adjust it based on how your eyes respond over time. If your symptoms improve significantly, we might reduce the frequency of some treatments or try tapering certain medications. However, complete discontinuation of treatment is rarely possible in chronic ocular GVHD, since stopping therapy often leads to symptom recurrence.
If your condition worsens despite treatment, we escalate therapy by adding new medications, increasing the frequency of existing drops, or trying advanced treatments like autologous serum tears or scleral contact lenses. Escalation can include scleral lenses or amniotic membrane therapy when surface disease persists despite medical therapy. Changes in your systemic GVHD status, new medications from your transplant doctor, or the development of complications like infections may also prompt us to modify your eye care plan.
Your best outcomes depend on close communication between all your doctors. We send regular updates to your transplant physician about your eye condition and treatments. When your transplant team adjusts your immunosuppressive medications, we monitor how those changes affect your eyes. If you develop new symptoms or complications, we collaborate to determine whether they relate to GVHD, your medications, or other factors.
This partnership also helps us plan for the future. Your transplant team provides insight into the expected course of your systemic GVHD, which helps us anticipate changes in your eye condition. We coordinate timing of treatments so that procedures or medication changes do not interfere with your overall care. Together, we aim to maintain your vision and eye comfort while supporting your recovery from transplant and management of GVHD.
Frequently Asked Questions
Currently, there is no proven way to completely prevent ocular GVHD if you develop chronic GVHD after your transplant. The immunosuppressive medications your transplant team prescribes help reduce your overall risk of GVHD, including eye involvement. Starting preservative-free artificial tears early after transplant and having regular eye examinations may help detect problems sooner, but these steps do not prevent the condition from developing.
Ocular GVHD is typically a chronic condition, meaning it lasts for months to years and may never fully resolve. With proper treatment, many patients achieve good symptom control and maintain comfortable eyes and stable vision. Some people experience gradual improvement over time, especially if their systemic GVHD is well controlled, but complete resolution is uncommon. Lifelong management is usually necessary.
Children can develop ocular GVHD after bone marrow or stem cell transplants, though pediatric transplants are less common overall. The condition affects both children and adults similarly in terms of symptoms and the types of eye structures involved. However, children may have more difficulty describing their symptoms, so careful observation and regular eye examinations are especially important. Treatment approaches are generally similar, though medication dosing and certain treatment options may differ based on age.
Standard soft or rigid contact lenses are usually not recommended when you have active ocular GVHD because they can further irritate your already inflamed and dry eye surface. However, specialized large-diameter scleral contact lenses may actually be part of your treatment in severe cases. These lenses vault over your cornea and hold a reservoir of fluid against your eye, providing constant moisture and protection. We evaluate each patient individually to determine whether any type of contact lens use is appropriate. If scleral lenses are prescribed, we will train you in strict hygiene. Only preservative-free sterile saline should be used to fill the lenses and tap water should never contact the lenses or case.
Ocular GVHD itself does not directly cause cataracts, but both the chronic inflammation and the treatments you receive can increase your risk. Corticosteroid medications, whether you use steroid eye drops or take oral steroids for systemic GVHD, raise your risk of developing cataracts over time. We monitor for cataract formation during your regular visits. The chronic inflammation from ocular GVHD can also increase your risk of corneal complications, infections, and scarring if not well controlled.
Acute GVHD typically occurs within the first 100 days after your transplant and rarely involves the eyes significantly. Chronic GVHD develops later, usually after three months post-transplant, and is much more likely to cause eye symptoms. Chronic GVHD is also a longer-lasting condition that requires ongoing treatment. When we talk about ocular GVHD, we are almost always referring to chronic GVHD, which causes the dry eye symptoms and eye surface inflammation that need specialized care.
Getting Help for Ocular Graft-Versus-Host Disease and Dry Eye
If you have undergone a bone marrow or stem cell transplant and are experiencing dry eye symptoms, burning, or vision changes, we encourage you to schedule an eye examination promptly. Early diagnosis and treatment of ocular GVHD can help protect you from serious complications and maintain your vision. Our eye doctor has experience managing this complex condition and will work with your transplant team to develop a comprehensive care plan tailored to your needs.